Literature DB >> 7629381

Overexpression of the c-MET/HGF receptor in human thyroid carcinomas derived from the follicular epithelium.

M F Di Renzo1, M Olivero, G Serini, F Orlandi, S Pilotti, A Belfiore, A Costantino, R Vigneri, A Angeli, M A Pierotti.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1995        PMID： 7629381     DOI： 10.1007/BF03349722

Source DB:  PubMed          Journal:  J Endocrinol Invest        ISSN： 0391-4097            Impact factor:   4.256


× No keyword cloud information.
  41 in total

1.  c-met is amplified but not mutated in a cell line with an activated met tyrosine kinase.

Authors:  C Ponzetto; S Giordano; F Peverali; G Della Valle; M L Abate; G Vaula; P M Comoglio
Journal:  Oncogene       Date:  1991-04       Impact factor: 9.867

2.  Partial transformation of human thyroid epithelial cells by mutant Ha-ras oncogene.

Authors:  N R Lemoine; S Staddon; J Bond; F S Wyllie; J J Shaw; D Wynford-Thomas
Journal:  Oncogene       Date:  1990-12       Impact factor: 9.867

3.  Tyrosine kinase receptor indistinguishable from the c-met protein.

Authors:  S Giordano; C Ponzetto; M F Di Renzo; C S Cooper; P M Comoglio
Journal:  Nature       Date:  1989-05-11       Impact factor: 49.962

4.  Cleavage of structural proteins during the assembly of the head of bacteriophage T4.

Authors:  U K Laemmli
Journal:  Nature       Date:  1970-08-15       Impact factor: 49.962

5.  Columnar-cell carcinoma. Another variant of poorly differentiated carcinoma of the thyroid.

Authors:  M Sobrinho-Simões; J M Nesland; J V Johannessen
Journal:  Am J Clin Pathol       Date:  1988-02       Impact factor: 2.493

6.  Molecular cloning of a new transforming gene from a chemically transformed human cell line.

Authors:  C S Cooper; M Park; D G Blair; M A Tainsky; K Huebner; C M Croce; G F Vande Woude
Journal:  Nature       Date:  1984 Sep 6-11       Impact factor: 49.962

7.  A new oncogene in human thyroid papillary carcinomas and their lymph-nodal metastases.

Authors:  A Fusco; M Grieco; M Santoro; M T Berlingieri; S Pilotti; M A Pierotti; G Della Porta; G Vecchio
Journal:  Nature       Date:  1987 Jul 9-15       Impact factor: 49.962

8.  Molecular cloning and sequence analysis of cDNA for human hepatocyte growth factor.

Authors:  K Miyazawa; H Tsubouchi; D Naka; K Takahashi; M Okigaki; N Arakaki; H Nakayama; S Hirono; O Sakiyama; K Takahashi
Journal:  Biochem Biophys Res Commun       Date:  1989-09-15       Impact factor: 3.575

9.  Expression of c-erbB-2 protein in papillary thyroid carcinomas.

Authors:  D R Haugen; L A Akslen; J E Varhaug; J R Lillehaug
Journal:  Br J Cancer       Date:  1992-06       Impact factor: 7.640

10.  Scatter factor and hepatocyte growth factor are indistinguishable ligands for the MET receptor.

Authors:  L Naldini; K M Weidner; E Vigna; G Gaudino; A Bardelli; C Ponzetto; R P Narsimhan; G Hartmann; R Zarnegar; G K Michalopoulos
Journal:  EMBO J       Date:  1991-10       Impact factor: 11.598
View more
  18 in total

1.  An overview of the c-MET signaling pathway.

Authors:  Shawna Leslie Organ; Ming-Sound Tsao
Journal:  Ther Adv Med Oncol       Date:  2011-11       Impact factor: 8.168

2.  Off-target effects of c-MET inhibitors on thyroid cancer cells.

Authors:  Yan Zhou; Conghui Zhao; Sigal Gery; Glenn D Braunstein; Ryoko Okamoto; Rocio Alvarez; Steven A Miles; Ngan B Doan; Jonathan W Said; Jiang Gu; H Phillip Koeffler
Journal:  Mol Cancer Ther       Date:  2013-10-29       Impact factor: 6.261

3.  Silencing of c-Met by RNA interference inhibits the survival, proliferation, and invasion of nasopharyngeal carcinoma cells.

Authors:  Yuncheng Li; Sulin Zhang; Zhengang Tang; Jian Chen; Weijia Kong
Journal:  Tumour Biol       Date:  2011-09-16

Review 4.  Signaling pathways as specific pharmacologic targets for neuroendocrine tumor therapy: RET, PI3K, MEK, growth factors, and Notch.

Authors:  Yvette Carter; Renata Jaskula-Sztul; Herbert Chen; Haggi Mazeh
Journal:  Neuroendocrinology       Date:  2012-02-14       Impact factor: 4.914

5.  c-MET as a potential therapeutic target and biomarker in cancer.

Authors:  J Rafael Sierra; Ming-Sound Tsao
Journal:  Ther Adv Med Oncol       Date:  2011-11       Impact factor: 8.168

Review 6.  Hepatocyte growth factor/scatter factor-induced intracellular signalling.

Authors:  K A Stuart; S M Riordan; S Lidder; L Crostella; R Williams; G G Skouteris
Journal:  Int J Exp Pathol       Date:  2000-02       Impact factor: 1.925

Review 7.  Molecular pathobiology of thyroid neoplasms.

Authors:  Giovanni Tallini
Journal:  Endocr Pathol       Date:  2002       Impact factor: 3.943

Review 8.  The Met oncogene and basal-like breast cancer: another culprit to watch out for?

Authors:  Stefania Gastaldi; Paolo M Comoglio; Livio Trusolino
Journal:  Breast Cancer Res       Date:  2010-08-23       Impact factor: 6.466

9.  Thyroid follicular oncogenesis in iodine-deficient and iodine-sufficient areas: search for alterations of the ras, met and bFGF oncogenes and of the Rb anti-oncogene.

Authors:  L Bartolone; F Vermiglio; M D Finocchiaro; M A Violi; D French; A Pontecorvi; F Trimarchi; S Benvenga
Journal:  J Endocrinol Invest       Date:  1998-11       Impact factor: 4.256

Review 10.  The PI3K-Akt-mTOR pathway in initiation and progression of thyroid tumors.

Authors:  Motoyasu Saji; Matthew D Ringel
Journal:  Mol Cell Endocrinol       Date:  2009-11-06       Impact factor: 4.102
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.